Advertisement
Canada markets close in 3 hours 20 minutes

  • S&P/TSX

    22,331.97
    -14.79 (-0.07%)
     

  • S&P 500

    5,320.58
    +13.57 (+0.26%)
     

  • DOW

    39,400.18
    -270.86 (-0.68%)
     

  • CAD/USD

    0.7301
    -0.0005 (-0.06%)
     

  • CRUDE OIL

    77.28
    -0.29 (-0.37%)
     

  • Bitcoin CAD

    93,255.41
    -2,927.99 (-3.04%)
     

  • CMC Crypto 200

    1,469.58
    -33.08 (-2.20%)
     

  • GOLD FUTURES

    2,345.80
    -47.10 (-1.97%)
     

  • RUSSELL 2000

    2,070.36
    -11.35 (-0.55%)
     

  • 10-Yr Bond

    4.4850
    +0.0510 (+1.15%)
     

  • NASDAQ

    16,939.67
    +138.12 (+0.82%)
     

  • VOLATILITY

    11.87
    -0.42 (-3.42%)
     

  • FTSE

    8,339.23
    -31.10 (-0.37%)
     

  • NIKKEI 225

    39,103.22
    +486.12 (+1.26%)
     

  • CAD/EUR

    0.6743
    -0.0002 (-0.03%)
     
MARKETS LIVE BLOG:

NASDAQ, S&P 500 PARE GAINS EVEN AS NVIDIA SUPPORTS

Boeing drops 5% as lack of deliveries to China expected to impact cash flow

AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference

Business Wire
·1 min read

WALTHAM, Mass., November 16, 2023--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York City, NY on Tuesday, November 28, 2023 at 10:00 a.m. ET.

A live webcast and archived replay of the presentation will be available on the Investors & Press section of the AlloVir website at https://ir.allovir.com.

About AlloVir

AlloVir is a leading late-clinical stage cell therapy company focused on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company's innovative and proprietary technology platform leverages off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir's technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio. For more information, visit www.allovir.com or follow us on Twitter/X or LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231116711808/en/

Contacts

Media and Investor:
ir@allovir.com